I’m guessing the various FDAs, especially the U
Post# of 148169
Quote:
I’m guessing the various FDAs, especially the U.S. FDA, will now give guidance on how to build on the reduction in mortality (100-200 more patients?)
Again, the safety and efficacy (even if slightly lower than expected) should earn LL an EUA and Phase 4. Unconscionable to do it any other way.